ICUI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ICU Medical Inc (ICUI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's recent financial performance shows declining revenue, net income, and EPS, which are significant red flags. While analysts have raised price targets and maintained an Overweight rating, the lack of clear positive catalysts, combined with bearish technical indicators and neutral trading sentiment, suggests that the stock does not present an optimal entry point currently. It is better to wait for improved financial performance or stronger technical signals before considering an investment.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 41.676, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 124.534), but overall, the technical indicators do not strongly support a buy decision.
Analysts have raised price targets to $178-$180 and maintained an Overweight rating, citing improved business operations and achievable guidance for 2026.
The company is under investigation for potential breaches of fiduciary duties, which could negatively impact shareholder confidence. Additionally, financial performance in Q4 2025 showed significant declines in revenue (-14.15% YoY), net income (-33.97% YoY), and EPS (-34.02% YoY).
In Q4 2025, revenue dropped to $540.7M (-14.15% YoY), net income fell to -$15.73M (-33.97% YoY), and EPS declined to -$0.64 (-34.02% YoY). However, gross margin improved to 37.54% (+4.05% YoY), showing some operational efficiency.
Analysts from KeyBanc and Piper Sandler have raised price targets to $180 and $178, respectively, and maintained Overweight ratings. They view the company as well-positioned for 2026, with improving business operations and achievable guidance.
